Cargando…

Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota

Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host–microbiome interaction, leading to a proinflammatory state. Alterations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendez-Sanchez, Nahum, Coronel-Castillo, Carlos Esteban, Cordova-Gallardo, Jacqueline, Qi, Xingshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603944/ https://www.ncbi.nlm.nih.gov/pubmed/37887176 http://dx.doi.org/10.3390/antibiotics12101475

Ejemplares similares

Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases
por: Hernández-Ceballos, Winston, et al.
Publicado: (2021)

Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?
por: Bai, Zhaohui, et al.
Publicado: (2021)

Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis
por: Xu, Guangqin, et al.
Publicado: (2023)

Current Therapies for Cholestatic Diseases
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2023)

Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis
por: Li, Hongyu, et al.
Publicado: (2018)

Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis
por: An, Yang, et al.
Publicado: (2021)

Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis
por: Li, Jing, et al.
Publicado: (2018)

Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
por: Barranco-Fragoso, Beatriz, et al.
Publicado: (2022)

Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2022)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Antibiotics, gut microbiota, and Alzheimer’s disease
por: Angelucci, Francesco, et al.
Publicado: (2019)

Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease
por: Giuli, Lucia, et al.
Publicado: (2023)

Nuclear Receptors in Nonalcoholic Fatty Liver Disease
por: López-Velázquez, Jorge A., et al.
Publicado: (2012)

The Gut Microbiota-Derived Immune Response in Chronic Liver Disease
por: Won, Sung-Min, et al.
Publicado: (2021)

Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases
por: Liu, Jing, et al.
Publicado: (2022)

The Gut Microbiota and Liver Disease
por: Llorente, Cristina, et al.
Publicado: (2015)

The varying effects of antibiotics on gut microbiota
por: Yang, Lulu, et al.
Publicado: (2021)

Antibiotic-Induced Dysbiosis of the Gut Microbiota Impairs Gene Expression in Gut-Liver Axis of Mice
por: Liu, Pu, et al.
Publicado: (2023)

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2019)

Antibiotics at birth and later antibiotic courses: effects on gut microbiota
por: Ainonen, Sofia, et al.
Publicado: (2021)

Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism
por: Mikkelsen, Kristian H., et al.
Publicado: (2015)

The Effect of Antibiotics on the Infant Gut Fungal Microbiota
por: Ventin-Holmberg, Rebecka, et al.
Publicado: (2022)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Antibiotics as Major Disruptors of Gut Microbiota
por: Ramirez, Jaime, et al.
Publicado: (2020)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
por: Torre, Aldo, et al.
Publicado: (2023)

Trust Your Gut: The Association of Gut Microbiota and Liver Disease
por: Manzoor, Ridda, et al.
Publicado: (2022)

Chronic kidney disease and gut microbiota
por: Amini Khiabani, Siamak, et al.
Publicado: (2023)

Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review
por: Xu, Shixue, et al.
Publicado: (2021)

The prophylactic effects of BIFICO on the antibiotic-induced gut dysbiosis and gut microbiota
por: Wu, Jiannong, et al.
Publicado: (2020)

Gut Microbiota and Host Reaction in Liver Diseases
por: Fukui, Hiroshi
Publicado: (2015)

Roles of Gut Microbiota in Alcoholic Liver Disease
por: Zhang, Daya, et al.
Publicado: (2023)

Effect of antibiotic gut microbiota disruption on LPS-induced acute lung inflammation
por: Jacobs, Max C., et al.
Publicado: (2020)

Gut microbiota response to antibiotics is personalized and depends on baseline microbiota
por: Rashidi, Armin, et al.
Publicado: (2021)

Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders
por: Karakan, Tarkan, et al.
Publicado: (2021)

Short-Term Effect of Antibiotics on Human Gut Microbiota
por: Panda, Suchita, et al.
Publicado: (2014)

Effects of Perinatal Antibiotic Exposure and Neonatal Gut Microbiota
por: Morreale, Chiara, et al.
Publicado: (2023)

Gut microbiota mediated molecular events and therapy in liver diseases
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Transient portal vein thrombosis in liver cirrhosis
por: Qi, Xingshun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_34p75o272l9fm2mubsmr84p8qi